BioAffinity Technologies Finalizes $3.2M Offering with 84% Potential Dilution to Address Going Concern

summarizeSummary

BioAffinity Technologies has finalized a $3.2 million public offering, including common stock and pre-funded warrants, to secure critical funding and address its going concern warning. The offering is highly dilutive, potentially increasing outstanding shares by 84%.

check_boxKey Events

• Public Offering Finalized

  The company is offering 1,040,000 shares of common stock and pre-funded warrants to purchase up to 2,960,000 shares, totaling 4,000,000 new shares.

• Pricing Details

  Common stock is offered at $0.80 per share, and pre-funded warrants at $0.7930 (exercisable at $0.007). This is a slight discount to the current stock price of $0.8172.

• Significant Capital Raise

  The offering aims to raise approximately $3.2 million in gross proceeds, with estimated net proceeds of $2.6 million, which is substantial relative to the company's market capitalization.

• Extreme Potential Dilution

  The offering could increase the number of outstanding shares by 84% (from 4,743,061 to 8,743,061 if all pre-funded warrants are exercised), leading to significant dilution for existing shareholders.

auto_awesomeAnalysis

This filing finalizes the terms of a public offering, critical for bioAffinity Technologies, Inc. to address its "going concern" warning and extend its cash runway beyond June 2026. The offering, which includes common stock and pre-funded warrants, could result in an 84% increase in outstanding shares, representing substantial dilution for existing shareholders. While securing capital is essential for the company's survival, the highly dilutive nature of the offering and the inclusion of warrants reflect the urgent need for financing.